Marra, Antonio http://orcid.org/0000-0002-7310-7824
Chandarlapaty, Sarat http://orcid.org/0000-0003-4532-8053
Modi, Shanu http://orcid.org/0000-0001-6427-7373
Article History
Accepted: 11 December 2023
First Online: 8 January 2024
Competing interests
: A.M. has received honoraria as a consultant, adviser or speaker from Roche and Menarini/Stemline. S.C. receives institutional grants and/or funding from AstraZeneca, Daiichi Sankyo and Lilly; has shares and/or ownership interests in Odyssey Biosciences and Totus Medicines; and has received honoraria as a consultant or adviser from AstraZeneca, Lilly, Prelude Therapeutics, Neogenomics, Novartis, Nuvalent and SAGA Diagnostics Effector Therapeutics. S.M. receives institutional funding for clinical research from AstraZeneca, Daiichi Sankyo, Genentech and Seagen; and has received honoraria as a consultant, adviser or speaker from AstraZeneca, Daiichi Sankyo, Eli Lilly, Genentech, Gilead, GlaxoSmithKline, Macrogenics, Puma Biotechnology, Seagen and Zymeworks.